NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-55039
Issuer: BIOTELEMETRY, INC.
Exchange: Nasdaq Stock Market LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address: 1010 Second Avenue
San Diego,
CALIFORNIA
92101
Telephone number: +1 619 243-7500
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
Common Stock
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
o 17 CFR 240.12d2-2(a)(1)
o 17 CFR 240.12d2-2(a)(2)
x 17 CFR 240.12d2-2(a)(3)
o 17 CFR 240.12d2-2(a)(4)
o  Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
o  Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements for the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2021-02-09ByO'Neil BlakeSenior Specialist
Date NameTitle
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more HeartBeam Charts.
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more HeartBeam Charts.

Biotelemetry, Inc. News

HeartBeam to Host First Quarter 2023 Results Conference Call on Thursday May 9, 2024 at 4:30 p.m. Eastern Time
Thursday 25 April 2024 (6 days ago) • Business Wire
HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias
Tuesday 9 April 2024 (3 weeks ago) • Business Wire
HeartBeam Reports Fourth Quarter and Full Year 2023 Financial Results
Wednesday 20 March 2024 (1 month ago) • Business Wire
First Patients Enrolled in Pivotal Study Evaluating HeartBeam’s AIMIGo™ System for Synthesizing a 12-Lead ECG
Thursday 14 March 2024 (2 months ago) • Business Wire
HeartBeam Receives Two New US Patents for its Core Cardiac Monitoring Technology
Thursday 7 March 2024 (2 months ago) • Business Wire
HeartBeam to Host Fourth Quarter and Full Year 2023 Results Conference Call on Wednesday March 20, 2024 at 4:30 p.m. Eastern Time
Tuesday 5 March 2024 (2 months ago) • Business Wire
HeartBeam Unveils AI Program Designed to Deliver Unprecedented Personalized Cardiac Insights
Thursday 14 December 2023 (5 months ago) • Business Wire
HeartBeam Reports Third Quarter 2023 Financial Results
Tuesday 14 November 2023 (6 months ago) • Business Wire
HeartBeam Announces Expansion of Its Scientific Advisory Board
Thursday 9 November 2023 (6 months ago) • Business Wire
HeartBeam Granted Third US Patent for 12-Lead Extended Wear Patch for Detecting Heart Attacks and Complex Cardiac Arrythmias
Tuesday 7 November 2023 (6 months ago) • Business Wire
HeartBeam to Host Third Quarter 2023 Results Conference Call on Tuesday November 14, 2023 at 4:30 p.m. Eastern Time
Tuesday 31 October 2023 (6 months ago) • Business Wire
Implicity Expands Senior Leadership Team with New U.S. Chief Commercial Officer
Wednesday 27 September 2023 (7 months ago) • PR Newswire (US)

More Biotelemetry, Inc. News Articles